trending Market Intelligence /marketintelligence/en/news-insights/trending/xK7W_j-BOI4oJQzQ70XTfQ2 content esgSubNav
In This List

D&D Pharmatech obtains $137.1M in series B round

Blog

Global Capital Markets & SPAC Activity – H1 2021

Blog

Banking Essentials Newsletter: July Edition - Part 3

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals


D&D Pharmatech obtains $137.1M in series B round

U.S.-based Octave Life Sciences and South Korean venture capital firm Smilegate Investment Inc. led a $137.1 million series B financing round for South Korean clinical-stage biotechnology company D&D Pharmatech Co. Ltd.

Current investors InterVest Co. Ltd., MAGNA Investment Co. Ltd. and LB Investment Inc. also participated in the round, together with individual shareholders/co-founders and employees from the U.S. and South Korea.

D&D Pharmatech focuses on the development and commercialization of revolutionary drugs through its three businesses Neuraly Inc., Precision Molecular Inc. and Theraly Fibrosis Inc.

Neuraly will use the capital to move a clinical candidate targeting neurodegenerative diseases into phase II trials, while Precision will use the funding to advance several neuroinflammation imaging agents into phase I and phase II trials. The capital will aid Theraly in advancing a preclinical candidate targeting fibrosis into a phase I/II trial.

D&D Pharmatech raised about $18.5 million in a series A round in March 2018, according to S&P Global Market Intelligence data.